SUMMARY:
Ciprofloxacin was evaluated along with other commonly used antibiotics against a total of 425 clinical isolates obtained from urine samples. Samples were collected from outdoor patients from different parts of Dhaka city. Susceptibility tests were done by the standardized disk diffusion method . Among the tested drugs, the percent susceptible rates observed were: ciprofloxacin (74%) , ampicillin (29%), cephalexin (54%) and trimethoprim-sulfamethoxazole (43%) tested against all organisms; gentamicin (73%) tested against gram-negative or -ganisms
and erythromycin (72%) tested against gram-positive organisms .
Ciprofloxacin showed better activity against gram-negative isolates (80%) compared to the other antibiotics. However, strains highly resistant to ciprofloxacin were detected among commonly isolated gram-negative urinary pathogens: Escherichia coli (18%), Klebsiella species (19%) and Pseudomonas species (30%) . Overall susceptibility rate for gram-positive cocci was significantly low for all the antibiotics tested including ciprofloxacin (62%). Minimal inhibitory concentration (MIC) of Ciprofloxacin was measured for all resistant and susceptible urinary tract infection (UTI) isolates. This study indicates emerging ciprofloxacin resistance among most UTI bacterial pathogens. Increasing resistance against ciprofloxacin demands coordinated monitoring of its activity, and rationale use of the antibiotic in UTI. INTRODUCTION Urinary tract infections are among the most common clinical problems in medical practice.
Enterobacteriaceae are responsible for most nonnosocomial, uncomplicated UTI, E, coli being the most common. Reports regarding ciprofloxacin resistance in Bangladesh show susceptibility of E, coli ranging from 60% in diabetic patients to 96% in nondiabetic patients (18).
Another study conducted on a pediatric population of 50 hospitalized patients, with UTI, showed 100% susceptibility of E, coil against ciprofloxacin (17). In contrast, another group in Pakistan has shown 81% susceptibility aganisnt ciprofloxacin in a pediatric population (19). Our study comprised of urban adult patients showed significant ciprofloxacin resistance among E, coil and most UTI bacterial pathogens. However, further study is required to establish any difference in susceptibility pattern of urinary pathogens against fluoroquinolones in the pediatric population. The results obtained in this study revealed several other antimicrobial susceptibility pattern: (a) ampicillin is the least effective antimicrobial agents studied here, with high resistance against the antibiotic being prevalent among all UTI pathogens including enterococci (b) trimethoprim-sulfamethoxazole (SXT) is becoming increasingly ineffective against most gram-negative bacilli and grampositive cocci (c) cephalexin and erythromycin show good activity against most Gram-positive cocci and appear to be more effective than ciprofloxacin. These observations regarding ampicillin, cephalexin or SXT efficacy are in concurrence with data from previous studies in our country (1) . On the other hand, gentamicin, appears to be more effective than ciprofloxacin against E, coli, the resistance rate being lower (15% vs. 18%). Due to its parenteral form and higher toxicity, gentamicin use has been somewhat limited in Bangladesh. Apparently, this may have restricted development of gentamicin resistance among E. coil isolates.
Most strains of commonly isolated gram-negative bacteria showed good susceptibility to ciprofloxacin and MIC's for these organisms were well below 0.5 mg/ml, with the exception of Pseudomonas species. On the other hand, ciprofloxacin and all other antibiotics included in the study showed moderate activities against gram positive isolates. Ciprofloxacin MIC was quite high among most resistant gram-positive isolates indicating a high level of fluroquinolone resistance among this group of UTI isolates. The incidence of multi-drug resistance was also high in case of ciprofloxacin-resistant S. aureus and coagulase-negative staphylococci. This may be explained by the increasing percentage of methicillin (oxacillin) resistance, about 30%, among staphylococcal isolates (unpublished data). Studies conducted in other regions indicate that cross-resistance occurs between oxacillin and fluroquinolones as a group, as well as other antibiotics (15).
The high incidence of multi-drug resistance among ciprofloxacin-resistant strains, as observed in our study, is significant in terms of infection control, particularly in hospitalized patients. This resistance to structurally unrelated antimicrobial agents indicate either mutations decreasing drug permeation or high prevalence of plasmid-mediated drug resistance, e.g., against aminoglycosides or cephalosporins (15,20). Similar surveillance studies conducted on both hospitalized and outdoor patients also indicate high incidence of multi-drug resistance. F. Jinnah and his co-workers have shown in their study that 34/65, i.e., 52% E, coli urinary isolates were resistant to four or more antibiotics, the incidence being 86% in hospitalized diabetic patients and 42% in non-diabetic outdoor patients (18). Our study has shown similar data in case of E. coli isolates of outdoor patients (Table I) . Attention should also be paid to emergence of oxacillin-resistant S. aureus strains which are more resistant not only to fluroquinolones but also to cephalosporins and carbapenems.
Most studies conducted abroad have indicated superiority of ofloxacin over ciprofloxacin, in terms of its activity against clinical isolates (15,16). We are now conducting a surveillance study comparing the activity of ciprofloxacin with other fluroquinolones and preliminary data indicate similar trends. The use of ofloxacin is almost negligible in our region and it may be considered as an alternative to ciprofloxacin, since there is an indication of emerging resistance against the latter. We recommend that national level antimicrobial surveillance studies be carried out to monitor emerging antimicrobial resistance to help clinicians determine better empiric, prophylactic and specific antibiotic therapy to obtain best clinical results. Use of ciprofloxacin should be more rationale and indiscriminate use of the drug should be discouraged. 
